Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE C versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE C versus QUIDE.
LOXITANE C vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine, a dibenzoxazepine antipsychotic, acts primarily by blocking dopamine D2 receptors in the brain. It also exhibits affinity for serotonin 5-HT2A receptors, alpha-adrenergic, histaminergic, and muscarinic receptors, contributing to its antipsychotic and sedative effects.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
10 mg orally twice daily initially; may increase by 10 mg/day every 3–4 days; usual therapeutic range 60–100 mg/day; maximum 250 mg/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 4-8 hours (mean 6 hours). Clinical context: Requires multiple daily dosing; stable plasma levels achieved by second day.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Approximately 70% renal (mainly as conjugated metabolites, <1% unchanged), 30% fecal via biliary excretion.
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic